Literature DB >> 27116710

Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors.

Katharina Mahal1, Bernhard Biersack1, Sebastian Schruefer1, Marcus Resch2, Ralf Ficner2, Rainer Schobert3, Thomas Mueller4.   

Abstract

5-(1-Methyl-4-phenyl-imidazol-5-yl)indoles 5 were prepared and tested as analogs of the natural vascular-disrupting agent combretastatin A-4 (CA-4). The 3-bromo-4,5-dimethoxyphenyl derivative 5c was far more active than CA-4 with low nanomolar IC50 concentrations against multidrug-resistant KB-V1/Vbl cervix and MCF-7/Topo mamma carcinoma cells, and also against CA-4-resistant HT-29 colon carcinoma cells. While not interfering markedly with the polymerization of tubulin in vitro, indole 5c completely disrupted the microtubule cytoskeleton of cancer cells at low concentrations. It also destroyed real blood vessels, both in the chorioallantoic membrane (CAM) of fertilized chicken eggs and within tumor xenografts in mice, without harming embryo or mouse, respectively. Indole 5c was less toxic than CA-4 to endothelial cells, fibroblasts, and cardiomyocytes. In highly vascularized xenograft tumors 5c induced distinct discolorations and histological features typical of vascular-disrupting agents, such as disrupted vessel structures, hemorrhages, and extensive necrosis. In a first preliminary therapy trial, indole 5c retarded the growth of resistant xenograft tumors in mice. © 2016 Elsevier Science Ltd. All rights reserved.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Combretastatin A-4; Imidazole; Indole; Mouse tumor xenografts; Vascular-disrupting agents

Mesh:

Substances:

Year:  2016        PMID: 27116710     DOI: 10.1016/j.ejmech.2016.04.045

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

Review 1.  Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

Authors:  Zaki S Seddigi; M Shaheer Malik; A Prasanth Saraswati; Saleh A Ahmed; Ahmed O Babalghith; Hawazen A Lamfon; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

2.  Molecular mechanism of cardol, isolated from Trigona incisa stingless bee propolis, induced apoptosis in the SW620 human colorectal cancer cell line.

Authors:  Paula Mariana Kustiawan; Kriengsak Lirdprapamongkol; Tanapat Palaga; Songchan Puthong; Preecha Phuwapraisirisan; Jisnuson Svasti; Chanpen Chanchao
Journal:  BMC Pharmacol Toxicol       Date:  2017-05-04       Impact factor: 2.483

Review 3.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

4.  Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.

Authors:  Tarek S Ibrahim; Mohamed M Hawwas; Azizah M Malebari; Ehab S Taher; Abdelsattar M Omar; Thikryat Neamatallah; Zakaria K Abdel-Samii; Martin K Safo; Yaseen A M M Elshaier
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

5.  Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.

Authors:  Franziska Reipsch; Bernhard Biersack; Henrike Lucas; Rainer Schobert; Thomas Mueller
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

6.  New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones.

Authors:  Gjorgji Atanasov; Rusi I Rusew; Vladimir M Gelev; Christo D Chanev; Rosica Nikolova; Boris L Shivachev; Ognyan I Petrov; Margarita D Apostolova
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.